Table 1. Baseline characteristics of lung cancer patients.
| Characteristic | Total (n=489) | Survivor (n=212) | Non-survivor (n=277) | p-value |
|---|---|---|---|---|
| Age | 69 (60‒74) | 63 (56‒72) | 71 (64‒76) | <0.001 |
| Male sex | 320 (65.4) | 120 (56.6) | 200 (72.2) | <0.001 |
| BMI, kg/m2 | 22.6 (20.3‒24.7) | 23.4 (21.2‒25.3) | 22.1 (19.7‒24.0) | <0.001 |
| Ever smoker | 298 (62.1) | 108 (52.2) | 190 (69.6) | <0.001 |
| Symptoms | ||||
| Asymptomatic | 64 (13.1) | 48 (22.6) | 16 (5.8) | <0.001 |
| Cough | 164 (33.5) | 53 (25.0) | 111 (40.1) | <0.001 |
| Sputum | 114 (23.3) | 39 (18.4) | 75 (27.1) | 0.024 |
| Dyspnea | 99 (20.2) | 30 (14.2) | 69 (24.9) | 0.003 |
| Hoarseness | 4 (0.8) | 1 (0.5) | 3 (1.1) | 0.637 |
| Hemoptysis | 32 (6.5) | 15 (7.1) | 17 (6.1) | 0.678 |
| Weight loss | 33 (6.7) | 10 (4.7) | 23 (8.3) | 0.117 |
| Performance status | <0.001 | |||
| 0–1 | 301 (85.8) | 140 (94.0) | 161 (79.7) | |
| 2–4 | 50 (14.2) | 9 (6.0) | 41 (20.3) | |
| Clinical staging (NSCLC) | <0.001 | |||
| I | 94 (25.6) | 87 (52.1) | 7 (3.5) | |
| II | 35 (9.5) | 23 (13.8) | 12 (6.0) | |
| III | 84 (22.9) | 29 (17.4) | 55 (27.5) | |
| IV | 154 (42.0) | 28 (16.8) | 126 (63.0) | |
| Clinical staging (SCLC) | 0.001 | |||
| Limited | 21 (36.8) | 9 (90.0) | 12 (25.5) | |
| Extensive | 30 (52.6) | 1 (10.0) | 29 (61.7) | |
| Unknown | 6 (10.5) | 0 (0) | 6 (12.8) | |
| EGFR mutation status (in adenocarcinoma) | 0.697 | |||
| Positive | 32 (13.4) | 18 (12.5) | 14 (14.9) | |
| Negative | 69 (29.0) | 40 (27.8) | 29 (30.9) | |
| Not checked | 137 (57.6) | 86 (59.7) | 51 (54.3) | |
| Any treatment after diagnosis | 374 (76.5) | 189 (89.2) | 185 (66.8) | <0.001 |
Values are expressed are expressed as number (%) or median (interquartile range).
BMI: body mass index; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; EGFR: epidermal growth factor receptor.